Last Updated : September 5, 2024
Details
Generic Name:
guselkumab
Project Status:
Pending
Therapeutic Area:
Ulcerative colitis
Manufacturer:
Janssen Inc.
Call for patient/clinician input open:
Brand Name:
Tremfya
Project Line:
Reimbursement Review
Project Number:
SR0874-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
The treatment of adult patients with moderately to severely active ulcerative colitis.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
The treatment of adult patients with moderately to severely active ulcerative colitis.
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : September 5, 2024